What is the last grey market premium of Accretion Pharmacueticals IPO?
Listing Review: Will update on listing.
Subscription status of Accrtion Pharmacueticals IPO
Accretion Pharmacueticals IPO Price Rs. 101 Lot 1200 shares, Rs. 33.99 Crore |
||||
QIB | NII x | RII x | Total x | Applications |
Note: . |
Accretion Pharmacueticals Allotment Link:
What is the business of Accretion Pharmacueticals?
Accretion Pharmacueticals IPO Details |
|
IPO opens on | 14 May 2025 |
IPO closes on | 16 May 2025 |
Issue Type | Book Built Issue IPO |
Issue Size | 2946000 Shares / Rs 29.75 Crore |
* Fresh Issue | 2946000 Shares / Rs 29.75 Crore |
* Offer for Sale – | – shares / Rs.- crore |
Market Maker Portion | 147600 Shares |
Net offer to Public | 2798400 Shares/ Rs 28.26 Crore |
Face Value per share | Rs. 10 |
Price Band | Rs. 101 |
Employee discount | Rs. 0 per share |
Retail Lot Size | 1200 Shares |
Listing will at | NSE SME |
Shares offered in IPO |
||
Shares | Rs. (Crore) | |
QIB (50%) | 1399200 | 14.13 |
HNI (15%) | 419760 | 4.24 |
RII (35%) | 979440 | 9.89 |
Total Shares | 2798400 | 28.26 |
Retail portion will be oversubscribed by |
816 | |
Forms | ||
How much Shares to Apply in this IPO? | ||
Min Retail Application | 1200 Shares | Rs.121200 |
Min HNI Application | 2400 Shares | Rs. 242400 |
Who are the Promoters of Accretion Pharmacueticals?
The promoters of the company are Mr. Mayur Popatlal Sojitra, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel and Mr. Hardik Mukundbhai Prajapati.
What are the Objects of Accretion Pharmacueticals IPO?
The Company proposes to utilize the Net Proceeds towards funding of the following objects:
a) Capital expenditure towards purchase of new equipment/ machineries, etc.
b) Capital expenditure towards upgradation of existing manufacturing facility
c) Repayment/prepayment of certain borrowings availed by the Company
d) Funding working capital requirements
e) General Corporate Purpose
Tentative timetable |
|
IPO opens on | 14 May 2025 |
IPO Closes on | 16 May 2025 |
IPO Allotment on | 19 May 2025 |
Refund Initiation | 20 May 2025 |
Credit of Shares | 20 May 2025 |
Listing on | 21 May 2025 |
Registered Office of the Company Accretion Pharmaceuticals Limited 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvad Sanand, Gujarat |
The Lead Manager of this IPO Jawa Capital Services Pvt Ltd |
Who is the Registrar to IPO? Kfin Technologies Ltd |
Accretion Pharmacueticals IPO GMP grey market premium, review, Subscription, allotment, listing estimate
Accretion Pharmacueticals Financials | ||||
Period Ended | 31-Dec-24 | 31-Mar-24 | 31-Mar-23 | 31-Mar-22 |
Assets | 39.99 | 27.05 | 20.58 | 17.74 |
Revenue | 35.75 | 33.94 | 29.53 | 22.58 |
Profit After Tax | 5.24 | 3.88 | 0.1 | 0.08 |
Net Worth | 13.58 | 5.35 | 3.84 | 3.08 |
Reserves and Surplus | 5.41 | 1.35 | 0 | 0 |
Total Borrowing | 13.79 | 13.48 | 8.47 | 7.61 |
Amount in ₹ Crore |
Key Performance Indicators | |
KPI | Values |
ROE | 72.47% |
ROCE | 36.73% |
Debt/Equity | 2.52 |
RoNW | 72.47% |
PAT Margin | 11.51 |
Price to Book Value | 7.55 |
EPS | 4.74 |
PE Ratio | 21.29 |
How Accretion Pharmacueticals IPO compares with the Peers?
Company Name | P/E (x) | RoNW (%) |
Accretion Pharmaceuticals | 11.56 | 38.54 |
Sakar Healthcare | 48.89 | 4.45 |
Lincoln Pharma | 12.3 | 15.74 |
Sotac Pharma | 23.85 | 11.91 |
# This is only coverage of News related to Grey Market Premium & subject to rates. We do not deal in grey market premium. We do not recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Accretion Pharmacueticals IPO Review by Paresh Gordhandas, CA & Research Analyst.
+ from grey market angle:
Quicklinks